CMG Pharmaceutical Co., Ltd.

KOSDAQ 058820.KQ

CMG Pharmaceutical Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2023: 38.18

CMG Pharmaceutical Co., Ltd. Interest Coverage Ratio is 38.18 for the year ending December 31, 2023, a -80.44% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

CMG Pharmaceutical Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2022 was 195.16, a 13.14% change year over year.
CMG Pharmaceutical Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2021 was 172.49, a 566.22% change year over year.
CMG Pharmaceutical Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2020 was 25.89, a -92.29% change year over year.
CMG Pharmaceutical Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2019 was 335.94.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

KOSDAQ: 058820.KQ

CMG Pharmaceutical Co., Ltd.

CEO	Joohyung Lee
IPO Date	Nov. 19, 2001
Location	South Korea
Headquarters	Cheongdam-dong 18-20, #B01
Employees	272
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years